Metabolomics paves the way for improved drug target identification
Correctly identifying candidate drugs for protein targets is crucial for drug discovery. Despite the importance of this problem for the pharmaceutical industry, chemical screening remains a challenging task, and drug–target misidentification may contribute to failures in drug development. In their recent study, Sauer and colleagues (Holbrook‐Smith et al, 2022) demonstrate proof‐of‐concept for a new way to identify drug–target interactions using high‐throughput metabolomics, potentially paving the way towards a universal method for predicting drug–target relationships.
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Metabolomics paves the way for improved drug target identification ; volume:18 ; number:2 ; year:2022 ; extent:2
Molecular systems biology ; 18, Heft 2 (2022) (gesamt 2)
- Urheber
-
Garana, Belinda B.
Graham, Nicholas A.
- DOI
-
10.15252/msb.202210914
- URN
-
urn:nbn:de:101:1-2022022314122903581768
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Garana, Belinda B.
- Graham, Nicholas A.
Ähnliche Objekte (12)
Improved drug therapy: triangulating phenomics with genomics and metabolomics
High‐throughput metabolomics predicts drug–target relationships for eukaryotic proteins
Improved batch correction in untargeted MS-based metabolomics
Integrating metabolomics and proteomics to identify novel drug targets for heart failure and atrial fibrillation
Evaluating the “wrong-way-round” electrospray ionization of antiretroviral drugs for improved detection sensitivity
Drug-drug relationship based on target information: application to drug target identification
Improved drug target deconvolution with PISA‐DIA using an extended, overlapping temperature gradient
Phosphodiesterases as drug targets
Transporters as drug targets
GWAS and drug targets
Pharmaco‐metabolomics opportunities in drug development and clinical research
L2,1-GRMF: an improved graph regularized matrix factorization method to predict drug-target interactions
Improved drug therapy: triangulating phenomics with genomics and metabolomics
High‐throughput metabolomics predicts drug–target relationships for eukaryotic proteins
Improved batch correction in untargeted MS-based metabolomics
Integrating metabolomics and proteomics to identify novel drug targets for heart failure and atrial fibrillation
Evaluating the “wrong-way-round” electrospray ionization of antiretroviral drugs for improved detection sensitivity
Drug-drug relationship based on target information: application to drug target identification
Improved drug target deconvolution with PISA‐DIA using an extended, overlapping temperature gradient
Phosphodiesterases as drug targets
Transporters as drug targets
GWAS and drug targets
Pharmaco‐metabolomics opportunities in drug development and clinical research
L2,1-GRMF: an improved graph regularized matrix factorization method to predict drug-target interactions
Improved drug therapy: triangulating phenomics with genomics and metabolomics
High‐throughput metabolomics predicts drug–target relationships for eukaryotic proteins
Improved batch correction in untargeted MS-based metabolomics
Integrating metabolomics and proteomics to identify novel drug targets for heart failure and atrial fibrillation
Evaluating the “wrong-way-round” electrospray ionization of antiretroviral drugs for improved detection sensitivity
Drug-drug relationship based on target information: application to drug target identification
Improved drug target deconvolution with PISA‐DIA using an extended, overlapping temperature gradient
Phosphodiesterases as drug targets
Transporters as drug targets
GWAS and drug targets
Pharmaco‐metabolomics opportunities in drug development and clinical research